['hepatitis c', 'hiv infection']
['sofosbuvir', 'ribavirin', 'sofosbuvir', 'ledipasvir']

        Inclusion Criteria:

          -  Age≥18 years

          -  Confirmed G1, G2 or G4 HCV infection

          -  Plasma HCV-RNA ≥1000 IU/mL

          -  No history of HCV treatment of any kind

          -  Willingness to use a birth control method (hormonal or intrauterine device for women,
             condoms for men), starting before HCV treatment initiation and continued until 4months
             (women) and 7 months (men) after end of treatment.

          -  Weight ≥40 kg and ≤125 kg

        For patients infected with HIV :

          -  Confirmed HIV-1 infection

          -  Stable HIV treatment for at least 8 weeks with two NRTIs (tenofovir or abacavir, and
             lamivudine or emtricitabine) and a third agent (raltegravir, lopinavir/ritonavir,
             atazanavir/ritonavir, darunavir/ritonavir, efavirenz, nevirapine)

          -  Current CD4+ lymphocytes count ≥100/mm3

          -  Current plasma HIV-1 RNA <200 copies/mL

        Exclusion Criteria:

        For each patient:

          -  Cirrhosis classified Child-Pugh B or C

          -  Co-infection by the Hepatitis B virus

          -  Pregnant or breastfeeding ongoing

          -  History of transplantation of organs or tissues

          -  Progressive Cancer, including hepatocellular carcinoma

          -  Epilepsy

          -  Sickle Cell Disease

          -  A history of myocardial infarction or other severe heart disease

          -  Excessive consumption of alcohol or drug users, in the absence of substitution by
             methadone, a stable weaning for more than three months should be required

          -  Ongoing Participation in another clinical trial

          -  Contraindications to the Sofosbuvir as defined in the Summary of Product
             Characteristics

          -  At least one of the following laboratory abnormalities:

        Haemoglobin <10 g / 100 ml (woman) <11 g / 100 ml (man) Platelet count <50,000 / mm3
        polymorphonuclear neutrophils rate <750 / mm3 Creatinine clearance <50ml / min

        For patients infected with HIV:

          -  Severe opportunistic infections in the last 6 months

          -  Poor adherence to antiretroviral treatment history

          -  Use of antiretroviral drugs other than those permitted in the test
      